Cancer is the abnormal proliferation of cells and neovascularisation (new blood vessel generation i. angiogenesis) which subsequent spread of other organs of the human body. The major therapeutic approaches of cancer treatment are chemotherapy to deliver the active pharmaceutical medicaments in the right dosage regimen to the targeted organ of malignant cells for predetermine time. Nanomedicine basically by passive as well as active targeting has fabricated for cancer chemotherapy and metastasizes phases.The advancement of nanomedicine will improve the therapeutic index of medicament molecule via modulation of pharmacokinetic profile as well as bio distribution during treatment of the diseases.

The field of the invention includes nanomedicine, oncology, and targeted drug delivery systems with a focus on the development of antibody-conjugated nanocarriers for precision cancer therapy, including the design of tamoxifen citrate loaded nanoliposomes tagged with FITC antihuman CD340 (erbB2/HER-2) antibody to perform active targeted killing against cancer cells in the breast. The present innovative investigation was fabricated by tamoxifen citrate incorporated lipid vesicles within nano range for recognize the neoplastic cells of breast tissues for active as well as passive targeting purpose. The monoclonal antibody such as FITC anti-human CD 340 (erbB2/HER-2) was tagged via the phosphoethanolamine which act as a linker molecule and conjugated to the bilayer surface of lipid vesicles.

Dr. Niladri Shekhar Dey has completed his PhD in Pharmacy in 2017 from the Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India. At present he is the professor and head of the department of Pharmaceutics of Mata Gujri College of Pharmacy, (Constituent unit of Mata Gujri University), Kishanganj, Bihar, INDIA. His area of research interested in nanomedicine and targeted drug delivery in cancer chemotherapy. He attended and presented his papers in various national and international conferences.He has publications in national and international peer reviewed journals with high impact factor and Indian patent in formulation patent in dual targeting for cancer chemotherapy.  He has written of various books and author of book chapters in international level in the field of pharmaceutical science. He is the reviewer of research and review articles in international journals. He was the plenary speaker of International conference in U.K. and Spain (Madrid) in 2023, 3rd, 4th and 9th International conference in U.K. Scintific Meditech 2024 and also plenary speaker in 2nd International webinar on Breast Cancer and Cancer Research (Scientex Conference).